Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Share:
Related SNY
JMP Sees A 'Negative Market Tone' In Biotechnology
Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients
What Is Beyond Vision-Loss Blockbuster For Regeneron? (Investor's Business Daily)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News

 

Related Articles (SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters